English
Human Fibroblast Growth Factor-9 Recombinant
Human Fibroblast Growth Factor-9 Recombinant
Artikelnummer
BPS90135-A
Verpackungseinheit
5 µg
Hersteller
BPS Bioscience
Verfügbarkeit:
wird geladen...
Preis wird geladen...
Products from BPS Bioscience require a minimum order value above 400€
Amino Acid Sequence: MAPLGEVGNY FGVQDAVPFG NVPVLPVDSP VLLSDHLGQS EAGGLPRGPA VTDLDHLKGI LRRRQLYCRT GFHLEIFPNG TIQGTRKDHS RFGILEFISI AVGLVSIRGV DSGLYLGMNE KGELYGSEKL TQECVFREQF EENWYNTYSS NLYKHVDTGR RYYVALNKDG TPREGTRTKR HQKFTHFLPR PVDPDKVPEL YKDILSQS
Background: FGF-9 is an autocrine and paracrine prostatic growth factor expressed by prostatic stromal cells. FGF-9 induces osteoblast proliferation and new bone formation in a bone organ assay. FGF-9 is produced by many prostate cancer cells and contributes to prostate cancer-induced new bone formation and may participate in the osteoblastic progression of prostate cancer in bone. It is also an autocrine and/or paracrine neurotrophic factor that promotes the survival of motoneurons and upregulates choline acetyl-transferase activity. FGF-9 enhances survival of AChE-positive neurons, increasing their mean soma size. It also up-regulates their choline acetyltransferase activity as potently as NGF and the effect is greater than that elicited by bFGF, CNTF, or GDNF. FGF-9 acts as a survival factor for neurons but does not promote neurite outgrowth. FGF-9 has been shown to mediate its effects by binding to FGF receptors. It efficiently activates the FGFR2c splice form of FGFR2 and the FGFR3b and FGFR3c splice isoforms of FGFR3.
Biological Activity: The ED50 was determined by the dose-dependent proliferation of mouse 3T3 cells expressing FGF receptors and was found to be in the range of 5 ng/ml.
Description: Recombinant Fibroblast Growth Factor-9 is a disulfide-linked monomer protein consisting of 208 amino acid residues, and migrates as an approximately 23 kDa protein under non-reducing and reducing conditions in SDS-PAGE.
Endotoxin Level: <0.1 ng/µg (1 EU/µg), using the LAL gel clot method.
Format: lyophilized protein
Formulation: Lyophilized from 0.2 µm filtered PBS solution.
Genbank: P31371
Purity: ≥95% by SDS-PAGE and HPLC
Reconstitution: Reconstitute at 0.1-1.0 mg/ml in distilled water. This solution can then be diluted into other buffers. To maximize product collection from vial surface, vortex briefly and then spin down to recollect the liquid.
Storage Stability: The lyophilized protein is stable for at least 2 years from date of receipt when stored at -20°C. Upon reconstitution, store in working aliquots at +4°C for up to one month, or at -20°C for up to six months, in the presence of a carrier protein. Avoid repeated freeze/thaw cycles.
Uniprot: P31371
Warnings: Avoid freeze/thaw cycles.
Biosafety Level: Not applicable (BSL-1)
References: 1. Deng M, et al. PLoS One. 2013 Aug 28,8(8):e72662.
2. Yin Y, et al. Cancer Res. 2013 Sep 15,73(18):5730-41.
Amino Acid Sequence: MAPLGEVGNY FGVQDAVPFG NVPVLPVDSP VLLSDHLGQS EAGGLPRGPA VTDLDHLKGI LRRRQLYCRT GFHLEIFPNG TIQGTRKDHS RFGILEFISI AVGLVSIRGV DSGLYLGMNE KGELYGSEKL TQECVFREQF EENWYNTYSS NLYKHVDTGR RYYVALNKDG TPREGTRTKR HQKFTHFLPR PVDPDKVPEL YKDILSQS
Background: FGF-9 is an autocrine and paracrine prostatic growth factor expressed by prostatic stromal cells. FGF-9 induces osteoblast proliferation and new bone formation in a bone organ assay. FGF-9 is produced by many prostate cancer cells and contributes to prostate cancer-induced new bone formation and may participate in the osteoblastic progression of prostate cancer in bone. It is also an autocrine and/or paracrine neurotrophic factor that promotes the survival of motoneurons and upregulates choline acetyl-transferase activity. FGF-9 enhances survival of AChE-positive neurons, increasing their mean soma size. It also up-regulates their choline acetyltransferase activity as potently as NGF and the effect is greater than that elicited by bFGF, CNTF, or GDNF. FGF-9 acts as a survival factor for neurons but does not promote neurite outgrowth. FGF-9 has been shown to mediate its effects by binding to FGF receptors. It efficiently activates the FGFR2c splice form of FGFR2 and the FGFR3b and FGFR3c splice isoforms of FGFR3.
Biological Activity: The ED50 was determined by the dose-dependent proliferation of mouse 3T3 cells expressing FGF receptors and was found to be in the range of 5 ng/ml.
Description: Recombinant Fibroblast Growth Factor-9 is a disulfide-linked monomer protein consisting of 208 amino acid residues, and migrates as an approximately 23 kDa protein under non-reducing and reducing conditions in SDS-PAGE.
Endotoxin Level: <0.1 ng/µg (1 EU/µg), using the LAL gel clot method.
Format: lyophilized protein
Formulation: Lyophilized from 0.2 µm filtered PBS solution.
Genbank: P31371
Purity: ≥95% by SDS-PAGE and HPLC
Reconstitution: Reconstitute at 0.1-1.0 mg/ml in distilled water. This solution can then be diluted into other buffers. To maximize product collection from vial surface, vortex briefly and then spin down to recollect the liquid.
Storage Stability: The lyophilized protein is stable for at least 2 years from date of receipt when stored at -20°C. Upon reconstitution, store in working aliquots at +4°C for up to one month, or at -20°C for up to six months, in the presence of a carrier protein. Avoid repeated freeze/thaw cycles.
Uniprot: P31371
Warnings: Avoid freeze/thaw cycles.
Biosafety Level: Not applicable (BSL-1)
References: 1. Deng M, et al. PLoS One. 2013 Aug 28,8(8):e72662.
2. Yin Y, et al. Cancer Res. 2013 Sep 15,73(18):5730-41.
| Artikelnummer | BPS90135-A |
|---|---|
| Hersteller | BPS Bioscience |
| Hersteller Artikelnummer | 90135-A |
| Green Labware | Nein |
| Verpackungseinheit | 5 µg |
| Mengeneinheit | STK |
| Produktinformation (PDF) |
|
| MSDS (PDF) |
|
Immer für Sie da
Gernot Ensinger, M.Sc.
Laurent Haze
